Form 6-K Abcam plc For: May 18
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2022
Commission File Number: 001-39633
(Translation of registrants name into English)
Cambridge Biomedical Campus
Cambridge, CB2 0AX
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On May 18, 2022, Abcam plc (the Company) issued a regulatory news service announcement (the Announcement) announcing the results of its Annual General Meeting held at Abcam Cambridge, UK headquarters on May 18, 2022. The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.
|99.1||Regulatory News Service Announcement dated May 18, 2022|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: May 18, 2022||By:|
|Title:||Chief Executive Officer|
For immediate release
18 May 2022
(Abcam or the Company)
Result of Annual General Meeting
Abcam plc (AIM: ABC; NASDAQ: ABCM), a global leader in the supply of life science research tools, announces that all resolutions put to its Annual General Meeting (the AGM) held today were passed.
The Board is pleased that all resolutions have been approved by shareholders and notes that a minority of shareholders opposed Resolution 2 (advisory resolution to approve the Annual Report on Remuneration) and Resolution 3 (to approve the Remuneration Policy).
For the reasons stated in the Annual Report, the Board and the Remuneration Committee continue to believe that the Remuneration Policy aligns incentives to the long-term success of the business and the creation of sustainable long-term shareholder value.
The Board remains firmly committed to speaking with shareholders to ensure it fully understands their views and it will continue to constructively engage with those shareholders who were unable to support Resolutions 2 and 3.
Full details of the poll results are available at corporate.abcam.com.
For further information, please contact:
|Abcam||+ 44 (0) 1223 696 000|
|Marc Perkins, Company Secretary|
|Numis Nominated Advisor & Joint Corporate Broker||+ 44 (0) 20 7260 1000|
|Freddie Barnfield / Duncan Monteith|
|Morgan Stanley Joint Corporate Broker||+ 44 (0) 207 425 8000|
|Tom Perry / Luka Kezic|
|FTI Consulting||+ 44 (0) 20 3727 1000|
|Ben Atwell / Julia Bradshaw|
About Abcam plc
As an innovator in reagents and tools, Abcams purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcams ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcams worldwide customer base of approximately 750,000 life science researchers uses Abcams antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcams ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).
Please visit corporate.abcam.com to find out more.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, as well as statements that include the words expect, intend, plan, believe, project, forecast, estimate, may, should, anticipate and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: this annual general meeting, the remuneration policy, a regional or global health pandemic, including the novel coronavirus and its related variants (COVID-19), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavors; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption Risk Factors in Abcams prospectus pursuant to Rule 462(e) filed with the U.S. Securities and Exchange Commission (SEC) on 29 March 2022, which is on file with the SEC and is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in Abcams other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abcam: Appointment of Vice President of Investor Relations
- HP Announces Commencement of Exchange Offer and Consent Solicitation for Plantronics Notes
- Churchwick Partners and Rockledge Complete Sonesta Portfolio Acquisitions, Adding Another 347 Keys Across Three States
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!